Page 8 - K. Development and regeneration
P. 8

[K. Development and regeneration-6]



              Hydroxychloroquine modifies features of preeclampsia (PE)


                   phenotype in L-nitro-arginine methyl ester (L-NAME)


                                           induced-PE rat model



         Minji Choi¹˙²˙³, Jae Ryoung Hwang², Nagyeong Byun²˙³, Suk-Joo Choi³, Soo-young Oh³, Jung-Sun Kim⁴,

                                                   Cheong-Rae Roh³˙*


         ¹Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 16419, Korea, Republic

              of, ²Samsung biomedical research institute, Samsung Medical Center, Seoul 06351, Korea, Republic of,
            ³Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of
           Medicine, Seoul 06351, Korea, Republic of, ⁴Department of Pathology and Translational Genomics, Samsung

                 Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea, Republic of




        Hydroxychloroquine(HCQ),  known  as  an  antimalarial  drug,  has  been  widely  used  to  treat  lupus  even  during

        pregnancy. In a recent clinical study, our team confirmed that HCQ significantly decreased the risk of preeclampsia
        (PE), to below 80%, in pregnant women with lupus(Lupus 2019;28:722-730). However, the underlying mechanism of

        HCQ of decreasing risk of PE is not clear. In this study, we investigated how HCQ affects on the features of PE
        phenotype using L-NAME induced-PE rat models. Pregnant SD rats were divided into four groups; 1) control, 2) L-

        NAME group in which L-NAME(300 mg/L) in drinking water was administrated from GD 7 to 18, 3) HCQ group in
        which daily oral HCQ (10 mg/kg/day) was administrated from GD 7 to 18, and 4) L-NAME plus HCQ group. Our

        data  showed  HCQ  significantly  decreased  systolic  blood  pressure(149.4-152.4  to  138.5-142.1  mmHg,  GD12-16,
        P<0.05) and tended to alleviate fetal resorption(23.1 to 13.4 %, P=0.16) in PE rat model. HCQ mitigated plasma
        level of sFlt-1(63.0 to 47.8 pg/ml, P<0.05) and endothelin-1(0.61 to 0.45 pg/ml, P<0.01) but not PlGF, TNF-a and IL-

        6. Our study showed that HCQ mitigated L-NAME induced-hypertension, fetal resorption, elevation of plasma sFlt-

        1 and ET-1 in PE rat model, suggesting endothelial protective mechanism of HCQ.
   3   4   5   6   7   8   9   10   11   12   13